SECuRE Trial: Undetectable Disease With 67Cu-SAR-bisPSMA
SYDNEY, Australia, Feb. 23, 2026 — Clarity Pharmaceuticals announced a significant clinical milestone in the ongoing SECuRE Trial, reporting...
Alzheimer’s Disease ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma biopharma innovation Biotechnology Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance GCP Gene Therapy Healthcare Innovation Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody NSCLC Oncology oncology innovation oncology research Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory compliance targeted therapy
SYDNEY, Australia, Feb. 23, 2026 — Clarity Pharmaceuticals announced a significant clinical milestone in the ongoing SECuRE Trial, reporting...
BARCELONA, Spain, Oct. 8, 2025 — During the 2025 Annual Congress of the European Association of Nuclear Medicine (EANM...
